"10.1371_journal.pone.0065631","plos one","2013-06-11T00:00:00Z","Jan Weber; Justine D Rose; Ana C Vazquez; Dane Winner; Nicolas Margot; Damian J McColl; Michael D Miller; Miguel E Qui√±ones-Mateu","Institute of Organic Chemistry and Biochemistry, Prague, Czech Republic; Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, United States of America; School of Biomedical Sciences, Kent State University, Kent, Ohio, United States of America; University Hospital Translational Laboratory, University Hospitals Case Medical Center, Cleveland, Ohio, United States of America; Gilead Sciences, Inc., Foster City, California, United States of America; Department of Pathology, Case Western Reserve University, Cleveland, Ohio, United States of America","Conceived and designed the experiments: MEQ-M. Performed the experiments: JW JDR ACV DW NM DJM. Analyzed the data: JW MEQ-M. Contributed reagents/materials/analysis tools: MDM. Wrote the paper: MEQ-M.","Doug Wylie and Ariel Rhea (Diagnostic Hybrids, Inc., Athens, Ohio) were involved in the drug susceptibility assays. Diagnostic Hybrids, Inc. acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the Platform for Antiviral Resistance Testing and Vaccine Development project. NM, DJM, and MDM are employed by Gilead Sciences, the developer of elvitegravir which was used in this study. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","06","Jan Weber","JW",8,TRUE,1,6,2,1,TRUE,TRUE,FALSE,0,NA,FALSE
